메뉴 건너뛰기




Volumn 24, Issue 1, 2014, Pages 54-60

Surveillance for brain metastases in patients receiving systemic therapy for advanced melanoma

Author keywords

Brain metastases; melanoma; radiologic frequency

Indexed keywords

LACTATE DEHYDROGENASE;

EID: 84891956971     PISSN: 09608931     EISSN: 14735636     Source Type: Journal    
DOI: 10.1097/CMR.0000000000000022     Document Type: Article
Times cited : (11)

References (32)
  • 2
    • 0002241917 scopus 로고    scopus 로고
    • Metastatic brain tumors
    • Kaye AH, Laws ER, editors Philadelphia, PA: Churchill Livingstone
    • Sawaya R, Bindal RK, Lang FF, Abi-Said D. Metastatic brain tumors. In: Kaye AH, Laws ER, editors. Brain tumors. Philadelphia, PA: Churchill Livingstone; 2001. pp. 999-1026.
    • (2001) Brain Tumors , pp. 999-1026
    • Sawaya, R.1    Bindal, R.K.2    Lang, F.F.3    Abi-Said, D.4
  • 5
    • 79953781233 scopus 로고    scopus 로고
    • Prognostic factors for survival in melanoma patients with brain metastases
    • Davies MA, Liu P, McIntyre S, Kim KB, Papadopoulos N, Hwu WJ, et al. Prognostic factors for survival in melanoma patients with brain metastases. Cancer 2011; 117:1687-1696.
    • (2011) Cancer , vol.117 , pp. 1687-1696
    • Davies, M.A.1    Liu, P.2    McIntyre, S.3    Kim, K.B.4    Papadopoulos, N.5    Hwu, W.J.6
  • 6
    • 0030094932 scopus 로고    scopus 로고
    • Cranial irradiation after surgical excision of brain metastases in melanoma patients
    • Skibber JM, Soong SJ, Austin L, Balch CM, Sawaya RE. Cranial irradiation after surgical excision of brain metastases in melanoma patients. Ann Surg Oncol 1996; 3:118-123.
    • (1996) Ann Surg Oncol , vol.3 , pp. 118-123
    • Skibber, J.M.1    Soong, S.J.2    Austin, L.3    Balch, C.M.4    Sawaya, R.E.5
  • 7
    • 44849122610 scopus 로고    scopus 로고
    • Brain and leptomeningeal metastases from cutaneous melanoma: Survival outcomes based on clinical features
    • Raizer JJ, Hwu WJ, Panageas KS, Wilton A, Baldwin DE, Bailey E, et al. Brain and leptomeningeal metastases from cutaneous melanoma: survival outcomes based on clinical features. Neuro Oncol 2008; 10:199-207.
    • (2008) Neuro Oncol , vol.10 , pp. 199-207
    • Raizer, J.J.1    Hwu, W.J.2    Panageas, K.S.3    Wilton, A.4    Baldwin, D.E.5    Bailey, E.6
  • 8
    • 0027947444 scopus 로고
    • Pilot study of preoperative chemotherapy with cisplatin, vinblastine, and dacarbazine in patients with local-regional recurrence of melanoma
    • Buzaid A, Legha SS, Balch CM, Ross M, Ring S, Plager C, et al. Pilot study of preoperative chemotherapy with cisplatin, vinblastine, and dacarbazine in patients with local-regional recurrence of melanoma. Cancer 1994; 74:2476-2482.
    • (1994) Cancer , vol.74 , pp. 2476-2482
    • Buzaid, A.1    Legha, S.S.2    Balch, C.M.3    Ross, M.4    Ring, S.5    Plager, C.6
  • 9
    • 0032428422 scopus 로고    scopus 로고
    • Phase II study of neoadjuvant concurrent biochemotherapy in melanoma patients with local-regional metastases
    • Buzaid AC, Colome M, Bedikian A, Eton O, Legha SS, Papadopoulos N, et al. Phase II study of neoadjuvant concurrent biochemotherapy in melanoma patients with local-regional metastases. Melanoma Res 1998; 8:549-556.
    • (1998) Melanoma Res , vol.8 , pp. 549-556
    • Buzaid, A.C.1    Colome, M.2    Bedikian, A.3    Eton, O.4    Legha, S.S.5    Papadopoulos, N.6
  • 10
    • 0037089629 scopus 로고    scopus 로고
    • Sequential biochemotherapy versus chemotherapy for metastatic melanoma: Results from a phase III randomized trial
    • Eton O, Legha SS, Bedikian AY, Lee JJ, Buzaid AC, Hodges C, et al. Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial. J Clin Oncol 2002; 20:2045-2052.
    • (2002) J Clin Oncol , vol.20 , pp. 2045-2052
    • Eton, O.1    Legha, S.S.2    Bedikian, A.Y.3    Lee, J.J.4    Buzaid, A.C.5    Hodges, C.6
  • 11
    • 59549100740 scopus 로고    scopus 로고
    • A phase III randomized trial of adjuvant biochemotherapy (BC) versus interferon-a-2b (IFN) in patients (pts) with high risk for melanoma recurrence
    • Kim KB, Legha SS, Gonzalez R, Anderson C, Papadopoulos NE, Eton O, et al. A phase III randomized trial of adjuvant biochemotherapy (BC) versus interferon-a-2b (IFN) in patients (pts) with high risk for melanoma recurrence. Melanoma Res 2009; 19:42-49.
    • (2009) Melanoma Res , vol.19 , pp. 42-49
    • Kim, K.B.1    Legha, S.S.2    Gonzalez, R.3    Anderson, C.4    Papadopoulos, N.E.5    Eton, O.6
  • 13
    • 0013613001 scopus 로고
    • A phase-II study of biochemotherapy using interleukin-2 (IL-2) + interferon alpha-2A (IFN) in combination with cisplatin (C), vinblastine (V) and DTIC (D) in patients with metastatic melanoma [abstract 1179]
    • Legha S, Plager C, Ring S. A phase-II study of biochemotherapy using interleukin-2 (IL-2) + interferon alpha-2A (IFN) in combination with cisplatin (C), vinblastine (V) and DTIC (D) in patients with metastatic melanoma [abstract 1179]. Proc Am Soc Clin Oncol 1992; 11:343.
    • (1992) Proc Am Soc Clin Oncol , vol.11 , pp. 343
    • Legha, S.1    Plager, C.2    Ring, S.3
  • 14
    • 0029906912 scopus 로고    scopus 로고
    • Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and dacarbazine (CVD) and biotherapy using interleukin-2 and interferon-alpha
    • Legha SS, Ring S, Bedikian A, Plager C, Eton O, Buzaid AC, et al. Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and dacarbazine (CVD) and biotherapy using interleukin-2 and interferon-alpha. Ann Oncol 1996; 7:827-835.
    • (1996) Ann Oncol , vol.7 , pp. 827-835
    • Legha, S.S.1    Ring, S.2    Bedikian, A.3    Plager, C.4    Eton, O.5    Buzaid, A.C.6
  • 15
    • 0031805726 scopus 로고    scopus 로고
    • Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma
    • Legha SS, Ring S, Eton O, Bedikian A, Buzaid AC, Plager C, Papadopoulos N. Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma. J Clin Oncol 1998; 16:1752-1759.
    • (1998) J Clin Oncol , vol.16 , pp. 1752-1759
    • Legha, S.S.1    Ring, S.2    Eton, O.3    Bedikian, A.4    Buzaid, A.C.5    Plager, C.6    Papadopoulos, N.7
  • 16
    • 0024448792 scopus 로고
    • A prospective evaluation of a triple-drug regimen containing cisplatin, vinblastine, and dacarbazine (CVD) for metastatic melanoma
    • Legha SS, Ring S, Papadopoulos N, Plager C, Chawla S, Benjamin R. A prospective evaluation of a triple-drug regimen containing cisplatin, vinblastine, and dacarbazine (CVD) for metastatic melanoma. Cancer 1989; 64:2024-2029.
    • (1989) Cancer , vol.64 , pp. 2024-2029
    • Legha, S.S.1    Ring, S.2    Papadopoulos, N.3    Plager, C.4    Chawla, S.5    Benjamin, R.6
  • 19
    • 84891908443 scopus 로고    scopus 로고
    • Long-term clinical results of the combination of cisplatin (C), vinblastine (V), DTIC (D) and interferon-alfa (I) with or without tamoxifen (T) for metastatic melanoma [abstract 8039]
    • Sanguino AM, Bedikian AY, Legha SS, Detry MA, Papadopoulos NE, Hwu P, et al. Long-term clinical results of the combination of cisplatin (C), vinblastine (V), DTIC (D) and interferon-alfa (I) with or without tamoxifen (T) for metastatic melanoma [abstract 8039]. J Clin Oncol 2006; 24:462s.
    • (2006) J Clin Oncol , vol.24
    • Sanguino, A.M.1    Bedikian, A.Y.2    Legha, S.S.3    Detry, M.A.4    Papadopoulos, N.E.5    Hwu, P.6
  • 20
    • 33845382806 scopus 로고
    • Nonparametric estimation from incomplete observations
    • Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53:457-481.
    • (1958) J Am Stat Assoc , vol.53 , pp. 457-481
    • Kaplan, E.L.1    Meier, P.2
  • 21
    • 0000120995 scopus 로고
    • A class of K-sample tests for comparing the cumulative incidence of a competing risk
    • Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988; 16:1141-1154.
    • (1988) Ann Stat , vol.16 , pp. 1141-1154
    • Gray, R.J.1
  • 22
    • 0037197627 scopus 로고    scopus 로고
    • Non-parametric confidence interval estimation for competing risks analysis: Application to contraceptive data
    • Choudhury JB. Non-parametric confidence interval estimation for competing risks analysis: application to contraceptive data. Stat Med 2002; 21:1129-1144.
    • (2002) Stat Med , vol.21 , pp. 1129-1144
    • Choudhury, J.B.1
  • 23
    • 1542532754 scopus 로고    scopus 로고
    • A proportional hazards model for the subdistribution of a competing risk
    • Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999; 94:496-509.
    • (1999) J Am Stat Assoc , vol.94 , pp. 496-509
    • Fine, J.P.1    Gray, R.J.2
  • 24
    • 0029130766 scopus 로고
    • Role of computed tomography in the staging of patients with local-regional metastases of melanoma
    • Buzaid AC, Tinoco L, Ross MI, Legha SS, Benjamin RS. Role of computed tomography in the staging of patients with local-regional metastases of melanoma. J Clin Oncol 1995; 13:2104-2108.
    • (1995) J Clin Oncol , vol.13 , pp. 2104-2108
    • Buzaid, A.C.1    Tinoco, L.2    Ross, M.I.3    Legha, S.S.4    Benjamin, R.S.5
  • 25
    • 79952987663 scopus 로고    scopus 로고
    • Pelvic computed tomography scans for surveillance in patients with primary melanoma in the head and neck
    • Alvarado GC, Papadopoulos NE, Hwu WJ, Bedikian AY, Homsi J, Myers JN, et al. Pelvic computed tomography scans for surveillance in patients with primary melanoma in the head and neck. Melanoma Res 2011; 21:127-130.
    • (2011) Melanoma Res , vol.21 , pp. 127-130
    • Alvarado, G.C.1    Papadopoulos, N.E.2    Hwu, W.J.3    Bedikian, A.Y.4    Homsi, J.5    Myers, J.N.6
  • 27
    • 0035940041 scopus 로고    scopus 로고
    • Treatment of brain metastases of malignant melanoma with temozolomide
    • Biasco G, Pantaleo MA, Casadei S. Treatment of brain metastases of malignant melanoma with temozolomide. N Engl J Med 2001; 345:621-622.
    • (2001) N Engl J Med , vol.345 , pp. 621-622
    • Biasco, G.1    Pantaleo, M.A.2    Casadei, S.3
  • 29
    • 33847355571 scopus 로고    scopus 로고
    • Therapeutic advances in the treatment of brain metastases
    • Chang JE, Robins HI, Mehta MP. Therapeutic advances in the treatment of brain metastases. Clin Adv Hematol Oncol 2007; 5:54-64.
    • (2007) Clin Adv Hematol Oncol , vol.5 , pp. 54-64
    • Chang, J.E.1    Robins, H.I.2    Mehta, M.P.3
  • 30
    • 84891953873 scopus 로고    scopus 로고
    • BREAK-MB: A phase II study assessing overall intracranial response rate (OIRR) to dabrafenib (GSK2118436) in patients with BRAF V600E/K mutation-positive melanoma with brain metastases (mets) [abstract 8501]
    • Kirkwood JM, Long GV, Trefzer U, Davies MA, Ascierto PA, Chapman PB, et al. BREAK-MB: A phase II study assessing overall intracranial response rate (OIRR) to dabrafenib (GSK2118436) in patients with BRAF V600E/K mutation-positive melanoma with brain metastases (mets) [abstract 8501]. J Clin Oncol 2012; 30:2012.
    • (2012) J Clin Oncol , vol.30 , pp. 2012
    • Kirkwood, J.M.1    Long, G.V.2    Trefzer, U.3    Davies, M.A.4    Ascierto, P.A.5    Chapman, P.B.6
  • 31
    • 84865072027 scopus 로고    scopus 로고
    • The NIBIT-MI trial: Activity of ipilimumab plus fotemustine in patients with melanoma and brain metastases [abstract]
    • Maio M, Testori A, Ascierto PA, et al. The NIBIT-MI trial: activity of ipilimumab plus fotemustine in patients with melanoma and brain metastases [abstract]. J Clin Oncol 2012; 30:8529.
    • (2012) J Clin Oncol , vol.30 , pp. 8529
    • Maio, M.1    Testori, A.2    Ascierto, P.A.3
  • 32
    • 77957587190 scopus 로고    scopus 로고
    • Phase II trial of ipilimumab monotherapy in melanoma patients with brain metastases [abstract 8523]
    • Lawrence DP, Hamid O, McDermott DF, et al. Phase II trial of ipilimumab monotherapy in melanoma patients with brain metastases [abstract 8523]. J Clin Oncol 2010; 28:15s.
    • (2010) J Clin Oncol , vol.28
    • Lawrence, D.P.1    Hamid, O.2    McDermott, D.F.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.